Recent Press Releases

Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program

Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program -- Small-Molecule Program Includes Commercial Opportunities For the...

Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome

BOSTON, July 6, 2015 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. ISIS, +0.04% announced today that the U.S. Food and Drug Administration has granted...

Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate)Modified Release Tablets

NEW YORK, Jul 02, 2015 (BUSINESS WIRE) -- Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) accepted for review Pfizer's new drug application (NDA) for...

Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial

MENLO PARK, Calif., July 6, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant...

Allergan to Acquire Oculeve Dry Eye Disease Development Programs

DUBLIN and SOUTH SAN FRANCISCO, Calif., July 6, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused...

Investigational HIV vaccine regimen shows encouraging results in non-human primates

Investigational HIV vaccine regimen shows encouraging results in non-human primates Johnson & Johnson announced today that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell...

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)

– Gilead's Third TAF-based Filing, Submitted with Priority Review Voucher – FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 1, 2015-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced...

Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson's Disease

Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson's Disease REHOVOT, Israel, June 30, 2015 /PRNewswire/ --...

Cell Therapy Ltd announces positive Phase II clinical trial results of Tendoncel™, a first-in-class topical regenerative medicine for severe tendon injury

Cell Therapy Ltd announces positive Phase II clinical trial results of Tendoncel™, a first-in-class topical regenerative medicine for severe tendon injury Cardiff, UK, June 30 2015 – Cell...

Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology

Companies to advance a potentially transformative treatment approach for genetic diseases of the eye AGTC to receive $124M upfront, with potential future milestone payments and royalties AGTC to host...

Flamel Technologies (FLML) Appoints SVP Of Quality And Regulatory Affairs And VP Of Business And Corporate Development

LYON, FRANCE--(Marketwired - June 26, 2015) - Flamel Technologies (NASDAQ: FLML) today announced the Company has appointed Sandy Hatten as Senior Vice President of Quality and Regulatory Affairs and...

Proteros biostructures GmbH Appoints Dr. Torsten Hoffmann As Chief Scientific Officer

Martinsried/Munich, Germany - 29 June 2015 - Proteros biostructures GmbH today announced the appointment of Dr. Torsten Hoffmann as Chief Scientific Officer (CSO), effective from July 1st, 2015. In...

vTv Therapeutics Appoints Rudy Howard as Chief Financial Officer

HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for...

Marathon Pharmaceuticals Names Joe Nolan Chief Commercial Officer

CHICAGO--(BUSINESS WIRE)--Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare diseases and neurological disorders, today announced that Joe Nolan has...

Enanta Pharmaceuticals, Inc. Announces The Appointment Of Nathalie Adda, M.D. As Chief Medical Officer

WATERTOWN, Mass., June 30, 2015 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral...

Vaccibody Appoints Martin Bonde As CEO

The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, 2015. Dr. Bonde has more than 25 years of international experience from the biotech...

DeNovo Sciences Appoints Dr. Yixin Wang, Former R&D Executive At Ventana And Veridex As Chief Scientific Officer

Plymouth | DeNovo Sciences, Inc. an innovator of cutting edge products of liquid biopsy, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in...

Catalyst Pharmaceuticals (CPRX) Appoints Dr. Gary Ingenito As Chief Medical Officer

CORAL GABLES, Fla., June 30, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...

Genisphere Appoints New CEO, Thomas Bliss

HATFIELD, Pa., June 30, 2015 /PRNewswire/ -- Genisphere announced Tom Bliss has joined the company as CEO to help further develop Genisphere's therapeutics capabilities and portfolio. Mr. Bliss...

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of Andrew Hack, M.D., Ph.D., as chief financial officer. Dr. Hack brings to...